Neonatal vancomycin continuous infusion: Still a confusion?

Pediatric Infectious Disease Journal

Volumn 33, Issue 6, 2014, Pages 600-605

  Gwee, Amanda ^a,b   Cranswick, Noel ^a,b,c   Metz, David ^a   Coghlan, Benjamin ^d,e   Daley, Andrew J ^a   Bryant, Penelope A ^a,b   Curtis, Nigel ^a,b,c  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d BURNET INSTITUTE   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Glycopeptide; infant; newborn; pharmacokinetics

Indexed keywords

CREATININE; GLUCOSE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; HUMAN; LOADING DRUG DOSE; NEWBORN; NEWBORN CARE; PARENTERAL NUTRITION; PRIORITY JOURNAL; SEPTICEMIA; SIDE EFFECT; SYSTEMATIC REVIEW; BLOOD; DRUG MONITORING; INTRAVENOUS DRUG ADMINISTRATION; NEONATOLOGY; PRACTICE GUIDELINE; PROCEDURES; PROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; DRUG MONITORING; HUMANS; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; NEONATOLOGY; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84901495892     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000243     Document Type: Article

References (30)

1. Foster JK Lentino JR Strodtman R et al. Comparison of in vitro activity of quinolone antibiotics and vancom ycin against gentamicin-and methicillin-resistant Staphylococcus aureus by time-kill kinetic studies. Antimicrob Agents Chemother. 1986;30:823-827. (Pubitemid 17209131)
2. Moise-Broder PA Forrest A Birmingham MC et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925-942. (Pubitemid 39447034)
3. Wysocki M Delatour F Faur isson F et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2001;45:2460-2467. (Pubitemid 32801896)
4. Cat aldo MA Tacconelli E Grilli E et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:17-24.
5. de Hoog M Mouton JW van den Anker JN. Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet. 2004;43:417-440. (Pubitemid 38716502)
6. Patel AD Anand D Lucas C et al. Continuous infusion of vancomycin in neonates. Arch Dis Child. 2013;98:478-479.
7. Zhao W Lopez E Biran V et al. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child. 2013;98:449-453.
8. Oudin C Vialet R Boulamery A et al. Vancomycin prescription in ne onates and young infants: toward a simplified dosage. Arch Dis Child Fetal Neonatal Ed. 2011;96:F365-F370.
9. Pawlotsky F Thomas A Kergueris MF et al. Constant rate infusion of vancomycin in premature neonates: a new dosage schedule. Br J Clin Pharmacol. 1998;46:163-167. (Pubitemid 28342788)
10. Plan O Cambonie G Barbotte E et al. Continuous-infusion vancomycin therapy for preterm neonates with suspec ted or documented Gram-positive infections: a new dosage schedule. Arch Dis Child Fetal Neonatal Ed. 2008;93:F418-F421.
11. Liu C Bayer A Cosgrove SE et al.; Infectious Diseases Society of Am erica. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-e55.
12. Rybak MJ Lomaestro BM Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America the American Society of Health-System Pharmacists and the Societ y of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49:325-327.
13. Samiee-Zafarghandy S van den Anker JN Do we really need continuous vancomycin infusion in neonates Arch Dis Child 2013 98 1023-1024
14. Schaible DH Rocci ML Jr. Alpert GA et al. Vancomycin pharmacokinetics in infants: relationships to indices of maturation. Pediatr Infect Dis. 1986;5:304-308. (Pubitemid 16115896)
15. Kumar A Roberts D Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589-1596. (Pubitemid 43810035)
16. Reed MD Kliegman RM Weiner JS et al. The clinical pharmacology of vancomycin in seriously ill preterm infants. Pediatr Res. 1987;22:360-363. (Pubitemid 17162804)
17. Kitzis MD Goldstein FW. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect. 2006;12: 92-95. (Pubitemid 43372248)
18. Center KJ Reboli AC Hubler R et al. Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus warneri. J Clin Microbiol. 2003;41:4660-4665. (Pubitemid 37259773)
19. Rybak MJ Lom aestro BM Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America the American Society of Health-System Pharmacists and the Society of Infectious Disea ses Pharmacists. Clin Infect Dis. 2009;49:325-327.
20. Fry moyer A Guglielmo BJ Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J. 2013;32:1077-1079.
21. Le J Bradley JS Murray W et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32:e155-e163.
22. Rello J Sole-Violan J Sa-Borges M et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med. 2005;33:1983-1987. (Pubitemid 41306519)
23. Anglada AM Ce rnadas JMC. Vancomycin-associated shock in neonates. Pediatr Infect Dis J. 1993;12:104-105.
24. Linder N Edwards R MeClead R et al. Safety of vancomycin with or without gentamicin in neonates. Neonatal Netw. 1993;12:27-30.
25. Jacqz-Aigrain E Zhao W Sharland M et al. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin F etal Neonatal Med. 2013;18:28-34.
26. Roberts JA Lipman J Blot S et al. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients Curr Opin Crit Care. 2008;14:390-396.
27. Raverdy V Ampe E Hecq JD et al. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother. 2013;68:1179-1182.
28. Szof C Walker PC. Incompatibility of cefotaxime sodium and vancomycin sulfate during Y-site administration. Am J Hosp Pharm. 1993;50: 2054-2057.
29. Gupta VD Stewart KR Nohria S. Stability of vancomycin hydrochloride in 5% dextrose and 0.9% sodium chloride injections. Am J Hosp Pharm. 1986;43:1729-1731. (Pubitemid 16059513)
30. Schilling CG Watson DM McCoy HG et al. Stability and delivery of vancomycin hydrochloride when admixed in a total parenteral nutrition solution. JPEN J Parenter Enteral Nutr. 1989;13:63-64. (Pubitemid 19041665)